This is a premixed vial of tesamorelin, CJC-1295 without DAC and ipamorelin, often 12 mg total (6 mg tesamorelin, 3 mg CJC-1295 and 3 mg ipamorelin, a 2:1:1 ratio). There's no standard ratio and other vials use other amounts, so dose from your own vial's label. Tesamorelin alone is FDA-approved for one use, but the other two and the blend are not.
How it works
Tesamorelin and CJC-1295 both copy the brain signal that tells your pituitary gland to release growth hormone, and ipamorelin copies a second signal that makes each release bigger. Since two of the three hit the same switch, they overlap more than they add up. Tesamorelin is the only one tested in big human trials.
What people use it for
Deep belly (visceral) fat
Body shape
Sleep and recovery
The evidence
Some human studies
Tesamorelin has the best data of any growth hormone peptide: in big trials in people with HIV, 2 mg a day cut deep belly fat by about 15% over 26 weeks, which led to FDA approval. Ipamorelin was selective for growth hormone in animals, and CJC-1295 without DAC has very little human data. No study has tested this three-way blend, and there's no evidence it does more than tesamorelin alone.
1–2 mg of blend (500 µg–1 mg tesamorelin + 250–500 µg each of CJC-1295 and ipamorelin, in a 2:1:1 vial)
How often
Once a day
When
Bedtime, on an empty stomach (at least 2 hours after food)
Cycle
8–12 weeks, often 5 days on and 2 days off, then a break of similar length
Route
Subcutaneous injection, usually the belly
Why: Dose by tesamorelin, the main part and the one listed first on most labels. A bedtime dose adds to your biggest natural growth hormone burst early in sleep, and food dulls the release. Example: add 3 mL of bacteriostatic water to a 12 mg vial. That makes 4 mg/mL of blend. A 1 mg dose is 0.25 mL, or 25 units on a U-100 insulin syringe. That gives 500 µg tesamorelin, 250 µg CJC-1295 and 250 µg ipamorelin. If your vial has a different ratio, redo this math.
Tesamorelin label dose (for reference)
Label dose
Dose
2 mg tesamorelin a day
How often
Once a day
When
Same time each day
Cycle
Ongoing under a doctor, with checks of blood sugar and IGF-1
Route
Subcutaneous injection, belly
Why: This is the approved dose of tesamorelin alone for HIV-related belly fat. Matching it with a 2:1:1 blend takes 4 mg of blend, which also brings 1 mg each of CJC-1295 and ipamorelin. That's far more of those two than people usually take. It's the main downside of a fixed ratio.
Start at the low end, and change one thing at a time. If you take medication or have a health condition, check with a doctor first.
We may earn a commission from these links. Counts include one syringe and two swabs per dose.
Stay safe
Side effects
Redness, itching or pain where you inject
Joint pain
Water retention and swollen hands or feet
Tingling or numb hands (like carpal tunnel)
Muscle aches
Flushing
Higher blood sugar
Headache
Side effects of all three add together, and you can't lower just one part
Skip it if
Any cancer now or in the past (growth hormone and IGF-1, a growth signal it raises, can feed cell growth)
Pregnant or breastfeeding (tesamorelin label)
Pituitary tumor, pituitary surgery, head radiation or other problems with the brain's hormone control (tesamorelin label)
Allergy to tesamorelin or mannitol (tesamorelin label)
Diabetes or prediabetes, unless a doctor is watching your blood sugar
Under 18
Competing in drug-tested sports
Interactions
Insulin and diabetes meds (growth hormone raises blood sugar)
Steroid meds like prednisone
Drugs your liver breaks down with the CYP3A4 enzyme: growth hormone can change their levels (tesamorelin label)
Don't stack with growth hormone itself or with other GHRH-type peptides (ones that copy the brain's release signal)
Get help right away for swelling of the face or throat, trouble breathing, chest pain, or a spreading, hot, red injection site.
Storage & legal
Storage
Powder: fridge or freezer. Mixed: fridge, use within about 4 weeks.
Legal status
FDA: Tesamorelin alone is approved (as Egrifta, 2010) to reduce excess belly fat in adults with HIV-related lipodystrophy. CJC-1295, ipamorelin and this blend are not approved.
Sport (WADA): Prohibited (S2: growth hormone releasing factors and secretagogues).
Common questions
What ratio is standard?
None. 6/3/3 mg in a 12 mg vial is common, but others exist. Always read your vial's label and dose by the tesamorelin amount.
Is the blend better than tesamorelin alone?
Unknown, since no study has tested it. Tesamorelin and CJC-1295 do nearly the same job, so a lot of the blend overlaps.
Can I take the full tesamorelin label dose with this blend?
You can, but you'll get much more CJC-1295 and ipamorelin than most people use. If you want 2 mg of tesamorelin, a plain tesamorelin vial is the cleaner choice.
Sources
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338
EGRIFTA (tesamorelin for injection) prescribing information. U.S. FDA. Source
Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822
Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176